GSK PLC closed 20.35% short of its 52-week high of £18.24, which the company achieved on May 16th.

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

London, UK Tuesday, February 25, 2025, 15:00 Hrs [IST] GSK plc (GSK) announces the commencement of its share buyback programme (the “Progr ...

GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

The company's consolidated net profit jumped multifold to Rs 230 crore as compared to Rs 46 crore a year ago in the December ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

The PMCPA has turned party pooper, coming down on GSK after learning that a U.K. employee celebrated a post about a ...

The Government of Canada has secured an initial supply of 500,000 doses of GSK's bird flu vaccine to protect individuals most ...

NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law ...

GSK PLC closed 20.87% below its 52-week high of £18.24, which the company reached on May 16th.